Economic and socio-behavioural issues related to highly active antiretroviral therapies for HIV infection: The contribution of social science research;Les enjeux économiques et sociaux de l'infection par le VIH à l'ère des multithérapies antirétrovirales: Apports des sciences humaines et sociales

Medecine/Sciences

Volumn 19, Issue 8-9, 2003, Pages 878-884

  Moatti, Jean Paul ^a,b   Spire, Bruno ^a,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Observatoire Regional de la Sante   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; DRUG EFFECT; EMPLOYMENT; EPIDEMIC; HEALTH CARE; HEALTH CARE POLICY; HEALTH ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT MONITORING; PROFESSIONAL PRACTICE; REVIEW; SEXUALITY; SOCIAL BEHAVIOR; SOCIAL SECURITY; SOCIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0141428024     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20031989878     Document Type: Review

References (52)

1. Bajos N, Bozon M, Ferrand A, Giami A, Spira A et le groupe ACSF. La sexualité aux temps du Sida. Paris: PUF, 1998.
2. Delor F, Hubert M. Revisiting the concept of vulnerability. Soc Sci Med 2000; 50: 1557-70.
3. Pierret J. Everyday life with AIDS/HIV: surveys in the social sciences. Soc Sci Med 2000; 50: 1589-98.
4. Moatti JP, Souteyrand Y. HIV/AIDS social and behavioural research: past advances and thoughts about the future. Soc Sci Med 2000; 50: 1519-32.
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
6. Bangsberg DR, Perry S, Charlebois ED, et al. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15: 1181-3.
7. Wainberg M, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279: 1977-83.
8. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 435-42.
9. Duran S, Solas C, Spire B, et al. Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy? A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS 2001; 15: 1075-7.
10. Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother 2001 35: 1010-5.
11. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AIDS clinical trials group (AACTG) adherence instruments. AIDS Care 2000; 12: 255-66.
12. Moatti JP, Spire B, Duran S. Un bilan des recherches socio-comportementales sur l'observance des traitements dons l'infection à VIH: au delà des modèles biomédicaux? Rev Epidemiol Santé Publ 2000; 48: 182-9.
13. Gordillo V, del Amo J, Soriano V, González-Lahoz J. Sociodemogrophic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13: 1763-9.
14. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 2002; 54: 1481-96.
15. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28: 445-9.
16. Duran S, Savès M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15: 2441-4.
17. Carrieri ID, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French national APROCO cohort. J Acquir Immune Defic Syndr 2001; 28: 232-9.
18. Nieuwkerk PT, Gisolf EH, Reijers MH, et al. Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS 2001; 15: 1985-91.
19. Low-Beer S, Chan K, Wood E, et al. Health related quality of life among persons with HIV after the use of protease inhibitors. Qual Life Res 2000; 9: 941-9.
20. Carrieri MP, Spire B, Duran S, et al. Health-related quality of life after one year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 32: 38-47.
21. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-9
22. Carrieri MP, Moatti JP, Vlahov D, et al. Access to antiretroviral treatment among French HIV-infected injection drug users (IDUs); the influence of continued drug use. J Epidemiol Community Health 1999; 53: 4-8.
23. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000; 14: 151-5.
24. Delfraissy JF. Prise en charge des personnes infectées par le VIH. Recommandations du groupe d'experts. Rapport 2002. Paris: Mé decine-Sciences/Flammarion, 2002.
25. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25: 221-8.
26. Hellinger FJ, Fleishman JA. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J Acquir Immune Defic Syndr 2000; 24: 182-8.
27. Sendi PP, Bucher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV cohort study. AIDS 1999; 13: 1115-22.
28. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. HIV cost and services utilization study corsortium. N Engl J Med 2001; 344: 817-23.
29. Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J Acquir Immune Defic Syndr 2001; 27: 14-9.
30. Garber A, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Eco 1997; 16: 1-31.
31. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-31.
32. Vernay-Vaisse C, Enel P, Ben Diane MK, Rey D, Carrieri MP, Obadia Y. Facteurs associés à la découverte de la séropositivité au VIH à un stade d'immunodépression avancé. BEH 2002; 15: 61-3.
33. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: an epidemic in transition. Am J Publ Health 2001; 91: 1060-8.
34. Ezzy D, De Visser R, Bartos M. Poverty, disease progression and employment among people living with HIV/AIDS in Australia. AIDS Care 1999; 11: 405-14.
35. Obadia Y, Marimoutou C, Bouhnik AD, Lert F, Dray-Spira R, Bousquet F. Les aides apportées aux personnes atteintes par l'infection à VIH-SIDA: une enquête auprès des patients des services de soins Île-de-France et en Provence-Alpes-Côte d'Azur. Etudes et Résultats. Paris: DREES, 2002; no 203.
36. Piketty C, Castiel P, Giral P, et al. Lack of legal income is strongly associated with an increased risk of AIDS and death in HIV-infected injecting drug users. AIDS Care 1999; 11: 429-36.
37. Fabre G, Tchobanian S. Les tensions actuelles entre le VIH et l'emploi. Sciences Sociales et Santé 2001; 19: 43-66.
38. Colson AE, Keller Marla J, Sax PE, Pettus PT, Platt R, Choo PW. Male sexual dysfunction associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30: 27-32.
39. Schiltz MA, Sandfort TG. HIV-positive people, risk and sexual behaviour. Soc Sci Med 2000; 50: 1571-88.
40. Lent F. Advances in HIV treatment and prevention: should treatment optimism lead to prevention pessimism? AIDS Care 2000; 12: 745-55.
41. Dukers NH, Spaargaren J, Geskus RB, Beijnen J, Coutinho RA, Fennema HS. HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections. AIDS 2002; 16: 19-24.
42. Adam P, Delmas MC, Brunet JB. Impact des nouveaux traitements antirétroviraux sur les attitudes et les comportements préventifs des lecteurs de la presse gay. De l'impact perçu par les individus à la mesure d'une influence effective. In: Lert F, Souteyrand Y, eds. Séropositivité, vie sexuelle et risque de transmission du VIH. Collection Sciences Sociales et Sida, Paris Agence Nationale de Recherche sur le Sida. 1999: 43-53.
43. Johnson AM, Mercer CH, Erens B, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001; 358: 1835-42.
44. Do AN, Hanson DL, Dworkin MS, Jones JL. Risk factors for and trends in gonorrhea incidence among persons infected with HIV in the United States. AIDS 2001; 15: 1149-55.
45. Van de Ven P, Kippax S, Knox S, Prestage G, Crawford J. HIV treatments optimism and sexual behaviour among gay men in Sydney and Melbourne. AIDS 1999; 13: 2289-94.
46. Scheer S, Chu PL, Klausner JD, Katz MH, Schwarcz SK. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. Lancet 2001; 357: 432-5.
47. Bouhnik AD, Moatti JP, Vlahov D, et al. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. J Epidemiol Commun Health 2002; 56: 349-53.
48. Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2000; 15: 1287-94.
49. Bayer R. Clinical progress and the future of HIV exceptionalism. Arch Intern Med 1999; 159: 1042-8.
50. Rosenbrock R, Dubois-Arber F, Moers M, Pinell P, Schaeffer D, Setbon M. The normalization of AIDS in Western European countries. Soc Sci Med 2000; 50: 1607-29.
51. Landman R, Moatti JP, Perrin V, Huard P and the PAMPA Study Group. Variability of attitudes toward early initiation of HAART for HIV infection: a study of French prescribing physicians. AIDS Care 2000; 12: 711-6.
52. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA 2001; 285: 1466-74.